國立虎尾科技大學 |

Biopharmaceutical Applied Statistics Symposium = Volume 3 Pharmaceutical Applications /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Biopharmaceutical Applied Statistics Symposium / edited by Karl E. Peace, Ding-Geng Chen, Sandeep Menon.
Reminder of title:	Volume 3 Pharmaceutical Applications /
other author:	Peace, Karl E.
Description:	XV, 426 p. 74 illus., 46 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Statistics . -
Online resource:	https://doi.org/10.1007/978-981-10-7820-0
ISBN:	9789811078200

Biopharmaceutical Applied Statistics Symposium = Volume 3 Pharmaceutical Applications /
Biopharmaceutical Applied Statistics Symposium Volume 3 Pharmaceutical Applications /[electronic resource] :edited by Karl E. Peace, Ding-Geng Chen, Sandeep Menon. - 1st ed. 2018. - XV, 426 p. 74 illus., 46 illus. in color.online resource. - ICSA Book Series in Statistics,2199-0980. - ICSA Book Series in Statistics,.

Part I: Personalized Medicine -- 1 Targeted Learning of Optimal Individualized Treatment Rules under Cost Constraints -- 2 Uses of Mixture Normal Distribution in Genomics and Otherwise -- 3 Personalized Medicine – Design Considerations -- 4 Adaptive Biomarker Subpopulation and Tumor Type Selection in Phase III Oncology Trials -- 5 High Dimensional Data in Genomics -- Part II: Novel Applications -- 6 Synergy or Additivity - The Importance of Defining the Primary Endpoint -- 7 Full Bayesian Adaptive Dose Finding using Toxicity Probability Interval (TPI) -- 8 Alpha-recycling for the Analyses of Primary and Secondary Endpoints of Clinical Trials -- 9 Expanded Interpretations of Results of Carcinogenicity Studies of Pharmaceuticals -- 1 Clinical Trials in Orphan Drug Development -- 11 Mediation Modeling in Randomized Trials with Non-normal Outcome Variables -- 12 Statistical Considerations in Using Images in Clinical Trials -- 13 Interesting Applications over 30 Years of Consulting -- 14 Uncovering Fraud, Misconduct and Other Data Quality Issues in Clinical Trials -- 15 Development and Evaluation of High Dimensional Prognostic Models -- 16 Design and Analysis of Biosimilar Studies.

This BASS book Series publishes selected high-quality papers reflecting recent advances in the design and biostatistical analysis of biopharmaceutical experiments – particularly biopharmaceutical clinical trials. The papers were selected from invited presentations at the Biopharmaceutical Applied Statistics Symposium (BASS), which was founded by the first Editor in 1994 and has since become the premier international conference in biopharmaceutical statistics. The primary aims of the BASS are: 1) to raise funding to support graduate students in biostatistics programs, and 2) to provide an opportunity for professionals engaged in pharmaceutical drug research and development to share insights into solving the problems they encounter. The BASS book series is initially divided into three volumes addressing: 1) Design of Clinical Trials; 2) Biostatistical Analysis of Clinical Trials; and 3) Pharmaceutical Applications. This book is the third of the 3-volume book series. The topics covered include: Targeted Learning of Optimal Individualized Treatment Rules under Cost Constraints, Uses of Mixture Normal Distribution in Genomics and Otherwise, Personalized Medicine – Design Considerations, Adaptive Biomarker Subpopulation and Tumor Type Selection in Phase III Oncology Trials, High Dimensional Data in Genomics; Synergy or Additivity - The Importance of Defining the Primary Endpoint, Full Bayesian Adaptive Dose Finding Using Toxicity Probability Interval (TPI), Alpha-recycling for the Analyses of Primary and Secondary Endpoints of Clinical Trials, Expanded Interpretations of Results of Carcinogenicity Studies of Pharmaceuticals, Randomized Clinical Trials for Orphan Drug Development, Mediation Modeling in Randomized Trials with Non-normal Outcome Variables, Statistical Considerations in Using Images in Clinical Trials, Interesting Applications over 30 Years of Consulting, Uncovering Fraud, Misconduct and Other Data Quality Issues in Clinical Trials, Development and Evaluation of High Dimensional Prognostic Models, and Design and Analysis of Biosimilar Studies.

ISBN: 9789811078200

Standard No.: 10.1007/978-981-10-7820-0doiSubjects--Topical Terms:

1253516
Statistics .

LC Class. No.: QA276-280

Dewey Class. No.: 519.5

Biopharmaceutical Applied Statistics Symposium = Volume 3 Pharmaceutical Applications /
LDR:04804nam a22004215i 4500 001 990618
003 DE-He213
005 20200704144604.0
007 cr nn 008mamaa
008 201225s2018 si | s |||| 0|eng d
020 $a 9789811078200 $9 978-981-10-7820-0
024 7 $a 10.1007/978-981-10-7820-0 $2 doi
035 $a 978-981-10-7820-0
050 4 $a QA276-280
072 7 $a PBT $2 bicssc
072 7 $a MED090000 $2 bisacsh
072 7 $a PBT $2 thema
072 7 $a MBNS $2 thema
082 0 4 $a 519.5 $2 23
245 1 0 $a Biopharmaceutical Applied Statistics Symposium $h [electronic resource] : $b Volume 3 Pharmaceutical Applications / $c edited by Karl E. Peace, Ding-Geng Chen, Sandeep Menon.
250 $a 1st ed. 2018.
264 1 $a Singapore : $b Springer Singapore : $b Imprint: Springer, $c 2018.
300 $a XV, 426 p. 74 illus., 46 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a ICSA Book Series in Statistics, $x 2199-0980
505 0 $a Part I: Personalized Medicine -- 1 Targeted Learning of Optimal Individualized Treatment Rules under Cost Constraints -- 2 Uses of Mixture Normal Distribution in Genomics and Otherwise -- 3 Personalized Medicine – Design Considerations -- 4 Adaptive Biomarker Subpopulation and Tumor Type Selection in Phase III Oncology Trials -- 5 High Dimensional Data in Genomics -- Part II: Novel Applications -- 6 Synergy or Additivity - The Importance of Defining the Primary Endpoint -- 7 Full Bayesian Adaptive Dose Finding using Toxicity Probability Interval (TPI) -- 8 Alpha-recycling for the Analyses of Primary and Secondary Endpoints of Clinical Trials -- 9 Expanded Interpretations of Results of Carcinogenicity Studies of Pharmaceuticals -- 1 Clinical Trials in Orphan Drug Development -- 11 Mediation Modeling in Randomized Trials with Non-normal Outcome Variables -- 12 Statistical Considerations in Using Images in Clinical Trials -- 13 Interesting Applications over 30 Years of Consulting -- 14 Uncovering Fraud, Misconduct and Other Data Quality Issues in Clinical Trials -- 15 Development and Evaluation of High Dimensional Prognostic Models -- 16 Design and Analysis of Biosimilar Studies.
520 $a This BASS book Series publishes selected high-quality papers reflecting recent advances in the design and biostatistical analysis of biopharmaceutical experiments – particularly biopharmaceutical clinical trials. The papers were selected from invited presentations at the Biopharmaceutical Applied Statistics Symposium (BASS), which was founded by the first Editor in 1994 and has since become the premier international conference in biopharmaceutical statistics. The primary aims of the BASS are: 1) to raise funding to support graduate students in biostatistics programs, and 2) to provide an opportunity for professionals engaged in pharmaceutical drug research and development to share insights into solving the problems they encounter. The BASS book series is initially divided into three volumes addressing: 1) Design of Clinical Trials; 2) Biostatistical Analysis of Clinical Trials; and 3) Pharmaceutical Applications. This book is the third of the 3-volume book series. The topics covered include: Targeted Learning of Optimal Individualized Treatment Rules under Cost Constraints, Uses of Mixture Normal Distribution in Genomics and Otherwise, Personalized Medicine – Design Considerations, Adaptive Biomarker Subpopulation and Tumor Type Selection in Phase III Oncology Trials, High Dimensional Data in Genomics; Synergy or Additivity - The Importance of Defining the Primary Endpoint, Full Bayesian Adaptive Dose Finding Using Toxicity Probability Interval (TPI), Alpha-recycling for the Analyses of Primary and Secondary Endpoints of Clinical Trials, Expanded Interpretations of Results of Carcinogenicity Studies of Pharmaceuticals, Randomized Clinical Trials for Orphan Drug Development, Mediation Modeling in Randomized Trials with Non-normal Outcome Variables, Statistical Considerations in Using Images in Clinical Trials, Interesting Applications over 30 Years of Consulting, Uncovering Fraud, Misconduct and Other Data Quality Issues in Clinical Trials, Development and Evaluation of High Dimensional Prognostic Models, and Design and Analysis of Biosimilar Studies.
650 0 $a Statistics . $3 1253516
650 0 $a Biostatistics. $3 783654
650 1 4 $a Statistics for Life Sciences, Medicine, Health Sciences. $3 670172
700 1 $a Peace, Karl E. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1132099
700 1 $a Chen, Ding-Geng. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 848229
700 1 $a Menon, Sandeep. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1208724
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9789811078194
776 0 8 $i Printed edition: $z 9789811078217
776 0 8 $i Printed edition: $z 9789811340062
830 0 $a ICSA Book Series in Statistics, $x 2199-0980 $3 1255207
856 4 0 $u https://doi.org/10.1007/978-981-10-7820-0
912 $a ZDB-2-SMA
912 $a ZDB-2-SXMS
950 $a Mathematics and Statistics (SpringerNature-11649)
950 $a Mathematics and Statistics (R0) (SpringerNature-43713)